Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

A Phase 2 Dose-Finding Trial of MY008211A in Complement Inhibitor-Naive Patients with Paroxysmal Nocturnal Hemoglobinuria and Signs of Active Hemolysis

Fengkui Zhang, Li Zhang, Miao Chen, Hongyan Tong, Xiaoni Li, Wei Wang, Li Liu, Geoffrey Ross

Blood (2024) 144 (Supplement 1): 2701.

https://doi.org/10.1182/blood-2024-210973

Published: 2024

Journal Articles

SLC25A1 Reprograms Mitochondrial and Fatty Acid Metabolism to Promote the Progression of Acute Myeloid Leukemia

Xiaojing Yan, Miao Chen, Yuan Tao, Sijing Kang, Pengjie Yue, Rui Ge

Blood (2024) 144 (Supplement 1): 2733.

https://doi.org/10.1182/blood-2024-203227

Published: 2024

Journal Articles

Ixazomib, Pomalidomide and Dexamethasone (IxaPD) Pan-Oral Regimen in the Treatment of Refractory and Relapsed Multiple Myeloma

Miao Chen, Hong Yu, Aijun Liu, Wei Wang, Xiaoqi Qin, Ziping Li, Yanping Ma, Wenming Chen, Rong Fu, Junling Zhuang

Blood (2024) 144 (Supplement 1): 7038.

https://doi.org/10.1182/blood-2024-210284

Published: 2024

Journal Articles

Adding Eltrombopag to Intensive Immunosuppressive Therapy Helps Adult Patients Catch up Pediatric Patients in Severe Aplastic Anemia

Bixi Yang, Leyu Wang, Lingling Fu, Runhui Wu, Jie Ma, Miao Chen, Bing Han

Blood (2024) 144 (Supplement 1): 5247.

https://doi.org/10.1182/blood-2024-193483

Published: 2024

Journal Articles

Long-Term Real-World Follow-up Study of Luspatercept for Lower-Risk Myelodysplastic Neoplasms

Zhuxin Zhang, Leyu Wang, Ziwei Liu, Chen Yang, Miao Chen, Bing Han, Junling Zhuang

Blood (2024) 144 (Supplement 1): 6730.

https://doi.org/10.1182/blood-2024-199403

Published: 2024

Journal Articles

Effective Treatment of Refractory Aplastic Anemia with Romiplostim after Failure of Multiple Thrombopoietin Receptor Agonists: A Single-Center Retrospective Study

Xijuan Lin, Chen Yang, Ziwei Liu, Junling Zhuang, Miao Chen, Bing Han

Blood (2024) 144 (Supplement 1): 4077.

https://doi.org/10.1182/blood-2024-200421

Published: 2024

Journal Articles

The Change of Complement Deposition after Complement Inhibitor Treatment in Paroxysmal Nocturnal Hemoglobinuria Patients

Menglu Zhang, Xuan Wang, Chen Yang, Miao Chen, Junling Zhuang, Bing Han

Blood (2023) 142 (Supplement 1): 1350.

https://doi.org/10.1182/blood-2023-178384

Published: 2023

Journal Articles

Rituximab Plus Bortezomib for Refractory and Relapsed Warm Autoimmune Hemolytic Anemia：a Prospective, Single-Arm, Phase Ⅱ Trial

Xijuan Lin, Chen Yang, Junling Zhuang, Daobin Zhou, Miao Chen, Bing Han

Blood (2023) 142 (Supplement 1): 3829.

https://doi.org/10.1182/blood-2023-178625

Published: 2023

Journal Articles

Adding Hetrombopag to Cyclosporine a to Patients with Newly Diagnosed Transfusion-Dependent Non-Severe Aplastic Anemia-a Prospective Phase 2 Study

Shupei Shen, Zhuxin Zhang, Junling Zhuang, Qinglin Hu, Miao Chen, Bing Han

Blood (2023) 142 (Supplement 1): 5005.

https://doi.org/10.1182/blood-2023-184471

Published: 2023

Journal Articles

Ixazomib, Pomalidomide and Dexamethasone (IxaPD) Pan-Oral Regimen in the Treatment of Refractory and Relapsed Multiple Myeloma

Miao Chen, Rong Fu, Wenming Chen, Wei Wang, Yanping Ma, Junling Zhuang

Blood (2023) 142 (Supplement 1): 6696.

https://doi.org/10.1182/blood-2023-187828

Published: 2023

Journal Articles

Transcriptomic Profile of Peripheral Blood Mononuclear Cells in Sirolimus-Sensitive Acquired Pure Red Cell Aplasia Patients

Yuan Yang, Qinglin Hu, Chen Yang, Miao Chen, Junling Zhuang, Bing Han

Blood (2023) 142 (Supplement 1): 5199.

https://doi.org/10.1182/blood-2023-179897

Published: 2023

Journal Articles

Myc Translocation Is an Adverse Factor Redefining High-Risk Multiple Myeloma

Xianghong Jin, Jianhua Du, Fujing Zhang, Hui Li, Shuangjiao Liu, Chen Yang, Miao Chen, Daobin Zhou, Junling Zhuang

Blood (2022) 140 (Supplement 1): 12575.

https://doi.org/10.1182/blood-2022-169332

Published: 2022

Journal Articles

The Value of PET/CT Combined with Next-Generation Flowcytometry in Minimal Residual Disease Detection and Prognostic Evaluation of Multiple Myeloma

Jianhua Du, Miao Chen, Li Huo, Wenjia Zhu, Huijuan Wang, Yun Leng, Shuangjiao Liu, Junling Zhuang

Blood (2022) 140 (Supplement 1): 7214.

https://doi.org/10.1182/blood-2022-165326

Published: 2022

Journal Articles

Immunosuppressive Therapy-Response Predicting Scoring System for Severe Aplastic Anemia

Xin Zhao, Li Zhang, Bing Han, Tiantian Zhang, Xu Liu, Miao Chen, Changping Li, Huijie Huang, Liping Jing, Kang Zhou, Guangxin Peng, Yuan Li, Jianping Li, Lei Ye, Huihui Fan, Wenrui Yang, Yingchang Mi, Fengkui Zhang

Blood (2022) 140 (Supplement 1): 5805–5806.

https://doi.org/10.1182/blood-2022-167951

Published: 2022

Journal Articles

Trial in Progress: A Perspective Study of Pan-Oral Triplet Regimen Pomalidomide, Ixazomib and Dexamethasone in Relapsed or Refractory Myeloma Patients

Miao Chen, Li Bao, Wenming Chen, Rong Fu, Rong Guo, Hongmei Jing, Hui Liu, Qinhua Liu, Yanping Ma, Xiuli SUN, Wei Wang, Yafei Wang, Xiaojing Yan, Jiang Qian, Junling Zhuang

Blood (2021) 138 (Supplement 1): 4783.

https://doi.org/10.1182/blood-2021-148237

Published: 2021

Journal Articles

Plasma Lipidome Acts As Diagnostic Marker and Predictor for Cyclosporin Response in Patients with Aplastic Anemia

Jing Ruan, Bing Han, Zhao Wang, Chen Yang, Yali Du, Miao Chen

Blood (2021) 138 (Supplement 1): 2199.

https://doi.org/10.1182/blood-2021-145843

Published: 2021

Journal Articles

Efficacy and Safety of Eltrombopag with or without Immunosuppressant in Patients with Relapsed/Refractory Acquired Aplastic Anemia: A Real-World Experience

Jiang Ji, Ziqi Wan, Jing Ruan, Yali Du, Miao Chen, Chen Yang, Zhao Wang, Bing Han

Blood (2021) 138 (Supplement 1): 1124.

https://doi.org/10.1182/blood-2021-145549

Published: 2021

Journal Articles

Plasma Concentration of Eltrombopag Correlated with the Efficacy in the Treatment of Refractory Aplastic Anemia: A Single-Center Study in China

Wei Zuo, Bo Zhang, Jing Ruan, Miao Chen, Jian Li, MD, Bing Han, MDPhD

Blood (2020) 136 (Supplement 1): 9.

https://doi.org/10.1182/blood-2020-134626

Published: 2020

Journal Articles

Home Treatment of Bortezomib: A Preliminary Exploration of a New Treatment Mode in China

Congli Zhang, Xin-xin Cao, Dong-zhu Li, Jun Feng, MD, Lu Zhang, MD, Yan Zhang, Ming-hui Duan, MD, Miao Chen, MD, Chen Yang, Wei Wang, Dao-Bin Zhou, Jian Li, MD

Blood (2019) 134 (Supplement_1): 2127.

https://doi.org/10.1182/blood-2019-125505

Published: 2019

Journal Articles

Methotrexate and Cytarabine for Adult Patients with Newly Diagnosed Langerhans Cell Histiocytosis: A Single Arm, Single Center, Prospective Phase 2 Study

Xinxin Cao, Jian Li, MD, Ai-lin Zhao, Xue-min Gao, Hua-cong Cai, MD, Lu Zhang, MD, Yan Zhang, MD, Jun Feng, MD, Miao Chen, MD, Tie-nan Zhu, MD, Na Niu, Jian Sun, MD, Zhi-yong Liang, MD, Dao-Bin Zhou, Ming-hui Duan, MD

Blood (2019) 134 (Supplement_1): 294.

https://doi.org/10.1182/blood-2019-122220

Published: 2019

NARROW

A Phase 2 Dose-Finding Trial of MY008211A in Complement Inhibitor-Naive Patients with Paroxysmal Nocturnal Hemoglobinuria and Signs of Active Hemolysis

SLC25A1 Reprograms Mitochondrial and Fatty Acid Metabolism to Promote the Progression of Acute Myeloid Leukemia

Ixazomib, Pomalidomide and Dexamethasone (IxaPD) Pan-Oral Regimen in the Treatment of Refractory and Relapsed Multiple Myeloma

Adding Eltrombopag to Intensive Immunosuppressive Therapy Helps Adult Patients Catch up Pediatric Patients in Severe Aplastic Anemia

Long-Term Real-World Follow-up Study of Luspatercept for Lower-Risk Myelodysplastic Neoplasms

Effective Treatment of Refractory Aplastic Anemia with Romiplostim after Failure of Multiple Thrombopoietin Receptor Agonists: A Single-Center Retrospective Study

The Change of Complement Deposition after Complement Inhibitor Treatment in Paroxysmal Nocturnal Hemoglobinuria Patients

Rituximab Plus Bortezomib for Refractory and Relapsed Warm Autoimmune Hemolytic Anemia：a Prospective, Single-Arm, Phase Ⅱ Trial

Adding Hetrombopag to Cyclosporine a to Patients with Newly Diagnosed Transfusion-Dependent Non-Severe Aplastic Anemia-a Prospective Phase 2 Study

Ixazomib, Pomalidomide and Dexamethasone (IxaPD) Pan-Oral Regimen in the Treatment of Refractory and Relapsed Multiple Myeloma

Transcriptomic Profile of Peripheral Blood Mononuclear Cells in Sirolimus-Sensitive Acquired Pure Red Cell Aplasia Patients

Myc Translocation Is an Adverse Factor Redefining High-Risk Multiple Myeloma

The Value of PET/CT Combined with Next-Generation Flowcytometry in Minimal Residual Disease Detection and Prognostic Evaluation of Multiple Myeloma

Immunosuppressive Therapy-Response Predicting Scoring System for Severe Aplastic Anemia

Trial in Progress: A Perspective Study of Pan-Oral Triplet Regimen Pomalidomide, Ixazomib and Dexamethasone in Relapsed or Refractory Myeloma Patients

Plasma Lipidome Acts As Diagnostic Marker and Predictor for Cyclosporin Response in Patients with Aplastic Anemia

Efficacy and Safety of Eltrombopag with or without Immunosuppressant in Patients with Relapsed/Refractory Acquired Aplastic Anemia: A Real-World Experience

Plasma Concentration of Eltrombopag Correlated with the Efficacy in the Treatment of Refractory Aplastic Anemia: A Single-Center Study in China

Home Treatment of Bortezomib: A Preliminary Exploration of a New Treatment Mode in China

Methotrexate and Cytarabine for Adult Patients with Newly Diagnosed Langerhans Cell Histiocytosis: A Single Arm, Single Center, Prospective Phase 2 Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only